Eikon Therapeutics’ IPO haul will support a lead program that could expand the scope of cancer immunotherapy. Eikon’s stock market debut builds on growing IPO momentum, following upsized offerings from Aktis Oncology and Veradermics.
The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 mutations. It will compete against an HER2-targeting Boehringer Ingelheim pill approved in August.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Takeda’s agreement with Innovent Biologics brings cancer drugs that could become contributors to a portfolio that’s facing the patent cliff. The pharmaceutical giant’s strategy for finding new blockbuster prospects spans internally discovered drugs and in-licensed assets.
Despite achieving statistically signficant improvement in progression-free survival in North American and European patients, Summit’s drug ivonescimab fell short of the other Phase 3 goal measuring overall survival. It’s the first Phase 3 readout for an emerging class of bispecific antibodies that treat cancer by blocking two targets, PD-1 and VEGF.
Johnson & Johnson has projected its lung cancer drug Rybrevant could achieve $5 billion in peak revenue. At the recent ASCO annual meeting, J&J executive Joshua Bauml explained his company’s strategy for this drug in lung cancer and beyond.
Bristol Myers Squibb’s partnership with BioNTech makes it the third big pharma company to strike a deal to gain access to a PD-L1/PD-1 and VEGF bispecific antibody with potential use in drug combinations to treat cancer. The deal calls for the two companies to share in the development of BioNTech’s drug and co-commercialize the asset globally.
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
Emrelis, an antibody drug conjugate developed by AbbVie, is now FDA approved for patients whose non-small cell lung cancer overexpresses the protein c-Met. The pharma company said this ADC is its first internally developed solid tumor medicine as well as its first solid tumor FDA approval in lung cancer.
Inspired by the speed and ease of at-home Covid-19 tests, OncoSwab is developing a test for lung cancer that detects signs of the disease from a nasal swab. The test could become an alternative to the medical imaging currently used to screen for lung cancer.
The FDA approved Novocure medical device Optune Luna as a treatment for advanced cases of non-small cell lung cancer. The wearable technology delivers electrical fields that kill cancer cells.
G1 Therapeutics turned research from the University of North Carolina at Chapel Hill into novel cancer drug Cosela, which is approved in the U.S. and China. Pharmacosmos says its G1 acquisition will enable Cosela to reach more lung cancer patients around the world.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
AI-powered solutions for opportunistic lung cancer detection using routine chest X-rays offer hope for improved early diagnosis and survival rates.
Palliative care provided by video was equivalent to in-person visits with a clinician, according to study results presented during the recent annual meeting of the American Society of Clinical Oncology. Investigators say these results indicate telehealth can make palliative care accessible to more cancer patients.
AstraZeneca’s Tagrisso and Imfinzi helped patients live longer in separate pivotal clinical trials evaluating the drugs in two different types of lung cancer. The results will be presented Sunday during the annual meeting of the American Society of Clinical Oncology.
Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space.
The FDA expanded the approval of Roche’s Alecensa to include adjuvant treatment of non-small cell lung cancer. The targeted therapy addresses cancers driven by the ALK genetic mutation.